retatrutide triple agonist obesity phase 2 trial Associated with Weight Loss of up to 24% in 48-Week Looking forward to when #retatrutide's

suggesting that the increase in eGFR is a pharmacodynamic effect unrelated to body mass changes

While stem cell therapy, PRP, and prolotherapy offer promising avenues for managing EDS, it is crucial to understand their limitations and potential risks

Ruf S, Rajagopal S, Kadnur SV, Hallur MS, Rani S, Kristam R, et al

Seniors are the group least likely to take GLP-1s GLP-1s are prescribed to treat chronic conditions that worsen with age, yet they're also powerful and preventative tools for weight loss among adults of all ages

Of the 3 studies which saw no difference in plasma carnitine in patients with AUDs compared to the control population, patients had no evidence of cirrhosis (Alonso De La Pena et al., 1990